BC
DYN icon

Bridgefront Capital’s Dyne Therapeutics DYN Stock Holding History

Bridgefront Capital’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-12,018
Closed -$235K – 593
2025
Q4 		$235K Sell
12,018
-6,024
-33% -$114K 0.06% 428
2025
Q3 		$228K Buy
+18,042
New +$206K 0.07% 484
2025
Q2 		– Sell
-15,540
Closed -$163K – 667
2025
Q1 		$163K Buy
+15,540
New +$222K 0.05% 551

Other funds holding DYN

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return

Bridgefront Capital's DYN Position: Q1 2026 in Review

Bridgefront Capital sold out of Dyne Therapeutics (DYN) in Q1 2026, closing a stake of 12,018 shares — an estimated $235K sold.

Bridgefront Capital first reported a position in DYN in Q1 2025 and held it in 3 quarters. The position peaked at $235K in Q4 2025. 227 funds tracked by Wall St. Rank hold DYN as of Q1 2026.

  • Bridgefront Capital reported no remaining Dyne Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Bridgefront Capital sold 12,018 Dyne Therapeutics shares in Q1 2026, an estimated $235K.
  • Bridgefront Capital first reported a position in Dyne Therapeutics in Q1 2025 and held it in 3 quarters.
  • Bridgefront Capital's Dyne Therapeutics position peaked at $235K in Q4 2025.
  • 227 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q1 2026.

Based on Bridgefront Capital's 13F filing for Q1 2026, filed 15 May 2026.